Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 market
11:00am, Friday, 08'th May 2026
Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for investors in the Danish...
Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 market
10:05am, Friday, 08'th May 2026
Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for investors in the Danish pharmaceutical giant. And both UBS and Citi are high
Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake
08:58am, Friday, 08'th May 2026
Eli Lilly's new oral weight-loss drug, Foundayo, was prescribed 7,335 times in the U.S. in the fourth week, a modest uptake compared to rival Novo Nordisk's Wegovy pill, analysts said.
Novo Nordisk India Sales Jump 40% As Generic Pressure Builds
08:21am, Friday, 08'th May 2026
Novo Nordisk A/S (NVO) may have just delivered an early warning shot in India's fast-moving obesity-drug market. Instead of watching demand buckle under the arr
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk
02:39pm, Thursday, 07'th May 2026
New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.
Forget Eli Lilly: These 2 Stocks Have More Upside
02:15pm, Thursday, 07'th May 2026
Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims
10:05am, Thursday, 07'th May 2026
Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO are two weight-loss and diabetes drug stocks that have been on completely different trajectories. Since the start of 2025, LLY is up near
Novo and Lilly gain on signs weight-loss pills could expand the market
08:15am, Thursday, 07'th May 2026
Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the market to millions more patients and help counter pric
While investors obsess over uptake of GLP-1 pills in the U.S., international sales are just as important.
My Top Obesity Stock to Buy and Hold
04:45am, Thursday, 07'th May 2026
Eli Lilly's Zepbound is already generating billions of dollars in revenue, making it the clear leader in a rapidly expanding market. Lilly's ability to produce and deliver creates a hurdle that smalle
Novo Nordisk: Mixed Q1 Does Not Break The Thesis, But Also Does Not Strengthen It
04:31pm, Wednesday, 06'th May 2026
Novo Nordisk A/S remains a cautious long, with Q1 2026 adjusted sales and EBIT under pressure but guidance raised on strong Wegovy pill uptake. NVO trades at a historically low 12.5x TTM P/E, reflecti
Novo Nordisk CEO: Open to deals, we need the broadest pipeline in the world
02:18pm, Wednesday, 06'th May 2026
CNBC's Angelica Peebles speaks with Novo Nordisk CEO Mike Doustdar about the company's quarterly report, the strong launch of the Wegovy pill and what else Novo Nordisk has to come in the pipeline. He
Novo Nordisk: Misread Q1 Earnings, Mispriced Stock
01:24pm, Wednesday, 06'th May 2026
Novo Nordisk A/S reported Q1 '26 headline growth, but adjusted EPS and revenue declined due to a one-off US 340B benefit exclusion. The NVO GLP-1 franchise, especially Wegovy, drives robust volume gro
NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up
12:55pm, Wednesday, 06'th May 2026
Novo Nordisk stock jumps as Q1 earnings and revenues beat estimates, fueled by strong Wegovy and Ozempic demand and a raised 2026 outlook.
Novo Nordisk A/S (NOVO:CA) Q1 2026 Earnings Call Transcript
12:21pm, Wednesday, 06'th May 2026
Novo Nordisk A/S (NOVO:CA) Q1 2026 Earnings Call Transcript
